Compare Gilead Sciences, Inc. (GILD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Gilead Sciences, Inc. trades at $134.85 (market cap $163.51B), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Gilead Sciences, Inc. is far larger — about 1698.6× Inovio Pharmaceuticals Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GILD | INO | |
|---|---|---|
Market Cap | $163.51B | $96.26M |
Sector | Health | Health |
52-Week High | $155.80 | $2.87 |
52-Week Low | $108.22 | $1.05 |
Enterprise Value | $178.05B | $67.27M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
